| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TARS | Common Stock | Sale | -$110K | -8K | -0.73% | $13.79 | 1.08M | Mar 15, 2023 | By the Bobak Azamian Living Trust established April 16, 2018 | F1, F2, F3 |
| transaction | TARS | Common Stock | Options Exercise | +11.3K | +645.66% | 13K | Mar 15, 2023 | Direct | F4 | ||
| transaction | TARS | Common Stock | Sale | -$10.6K | -791 | -6.06% | $13.43 | 12.3K | Mar 16, 2023 | Direct | F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TARS | Restricted Stock Units | Options Exercise | $0 | -11.3K | -25% | $0.00 | 33.9K | Mar 15, 2023 | Common Stock | 11.3K | Direct | F6, F7 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. |
| F2 | The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.52 to $14.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. |
| F4 | The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). |
| F5 | The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholdingobligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| F6 | Each RSU represents a contingent right to receive one share of the Company's common stock. |
| F7 | RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. |